Headway vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 74)
Headway logo

Headway

LeaderHealthcare

Mental Health Provider Network & Insurance Matching

Headway is the largest mental health platform connecting patients to in-network therapists and psychiatrists; $2.3B valuation after $100M Series D in July 2024; $321M raised; 34,000+ providers across all 50 US states.

AI VisibilityBeta
Overall Score
B74
Category Rank
#83 of 596
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
75
Perplexity
78
Gemini
72

About

Headway is the United States' largest mental health platform by provider network, connecting individuals seeking therapy and psychiatric care with in-network mental health professionals covered by their insurance. Founded in 2019 and headquartered in New York, Headway builds the infrastructure layer that allows mental health providers — therapists and psychiatrists — to easily accept insurance, handle billing and credentialing automatically, and manage their patient panels through a streamlined practice management platform. This eliminates the administrative burden that has historically caused the majority of mental health providers to operate as cash-pay only, significantly reducing access barriers for patients.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

74
Overall Score
90
#83
Category Rank
#2
81
AI Consensus
83
stable
Trend
stable
75
ChatGPT
92
78
Perplexity
93
72
Gemini
89
74
Claude
96
70
Grok
95

Key Details

Category
Mental Health Provider Network & Insurance Matching
Enterprise
Tier
Leader
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.